The use of cefepime for treating AmpC β-lactamase-producing enterobacteriaceae

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 781-788

  Tamma, Pranita D ^a   Girdwood, Sonya C T ^b   Gopaul, Ravindra ^c   Tekle, Tsigereda ^b   Roberts, Ava A ^b   Harris, Anthony D ^c   Cosgrove, Sara E ^a   Carroll, Karen C ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Department of Pathology   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AmpC lactamases; boronic acid; cefepime; Enterobacter; gram negative resistance

Indexed keywords

AZTREONAM; BETA LACTAMASE AMPC; CEFEPIME; CEFOTETAN; CLOXACILLIN; HYPERTENSIVE FACTOR; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BLOOD CULTURE; CITROBACTER; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ENZYME SYNTHESIS; EPSILOMETER TEST; FEMALE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SERRATIA;

AMPC Β-LACTAMASES; BORONIC ACID; CEFEPIME; ENTEROBACTER; GRAM-NEGATIVE RESISTANCE;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; COHORT STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROPENSITY SCORE; THIENAMYCINS;

EID: 84883238476     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit395     Document Type: Article

References (45)

1. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009; 22: 161-82, Table of Contents.
2. Park YS, Yoo S, Seo MR, Kim JY, Cho YK, Pai H. Risk factors and clinical features of infections caused by plasmid-mediated AmpC betalactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2009; 34:38-43.
3. Rand KH, Turner B, Seifert H, Hansen C, Johnson JA, Zimmer A. Clinical laboratory detection of AmpC beta-lactamase: does it affect patient outcome? Am J Clin Pathol 2011; 135:572-6.
4. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162:185-90.
5. Pai H, Kang CI, Byeon JH, et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:3720-8.
6. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC betalactamase-producing gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 2012; 40:297-305.
7. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
8. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45:2628-30.
9. Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL. Should third-generation cephalosporins be avoided against AmpCinducible Enterobacteriaceae? Clin Microbiol Infect 2004; 10:84-5.
10. Sanders WE Jr., Sanders CC. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 1997; 10:220-41.
11. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 1996; 100(6A):68S-75.
12. Food and Drug Administration. Information for Healthcare Professionals: Cefepime (marketed as Maxipime). Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ DrugSafetyInformationforHeathcareProfessionals/ucm167254. htm. Accessed 15May 2013.
13. Bell JM, Turnidge JD;, Cefepime Study Group. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents. Pathology 2001; 33:53-60.
14. Turnridge J, Gottlieb T, Mitchell D, Pearson J, Bell J. Gram-negative survey: 2008 antimicrobial susceptibility report. Australian Group on Antimicrobial Resistance (AGAR). Available at: http://www.agargroup. org/files/AGAR%20GNB09%20REPORT%20FINAL.pdf. Accessed 7 March 2013.
15. Ehrhardt AF, Sanders CC. Beta-lactam resistance amongst Enterobacter species. J Antimicrob Chemother 1993; 32(suppl B):1-11.
16. Neu HC, Chin NX, Jules K, Labthavikul P. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother 1986; 17:441-52.
17. Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993; 17:369-79.
18. Kang CI, Pai H, Kim SH, et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpCtype beta-lactamase. J Antimicrob Chemother 2004; 54:1130-3.
19. Limaye AP, Gautom RK, Black D, Fritsche TR. Rapid emergence of resistance to cefepime during treatment. Clin Infect Dis 1997; 25:339-40.
20. Department of Health and Human Services. Protection of human subjects. Title 45 CFR 46.116. General requirements for informed consent. 2009.
21. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
22. Kohner PC, Robberts FJ, Cockerill FR 3rd, Patel R. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase-and pAmpCproducing Escherichia coli and Klebsiella species. J Clin Microbiol 2009; 47:2419-25.
23. Coudron PE. Inhibitor-based methods for detection of plasmidmediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J Clin Microbiol 2005; 43:4163-7.
24. Song W, Jeong SH, Kim JS, et al. Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC betalactamases and extended-spectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis. Diagn Microbiol Infect Dis 2007; 57:315-8.
25. Engelhardt A, Yusof A, Ho P, Sjostrom K, Johansson C. Evaluation of a new Etest strip for AmpC detection using a large collection of genotypically characterized strains (Abstract D-280). In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2008.
26. Peter-Getzlaff S, Polsfuss S, Poledica M, et al. Detection of AmpC betalactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis. J Clin Microbiol 2011; 49:2924-32.
27. Yagi T, Wachino J, Kurokawa H, et al. Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 2005; 43:2551-8.
28. Jacoby GA, Walsh KE, Walker VJ. Identification of extended-spectrum, AmpC, and carbapenem-hydrolyzing beta-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests. J Clin Microbiol 2006; 44:1971-6.
29. Mérieux Cefotetan-cloxacillin Etest strips. Available at: http://www. biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/ dynPage? open=CNL-CLN-PRD&doc=CNL-CLN-PRD-G-PRD-CLN-22& pubparams.sform=0&lang=en. Accessed 15March 2013.
30. Cosgrove SE, Avdic E. Johns Hopkins Hospital Antibiotic Guidelines 2013-2014. Available at: www.hopkinsmedicine.org/amp. Accessed 12 May 2013.
31. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004; 39:812-8.
32. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C betalactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997; 28:211-9.
33. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36(suppl 3):S8-14.
34. Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:337-42.
35. van Ogtrop ML, Guiot HF, Mattie H, van Strijen E, Sekh BR, van Furth R. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam. Antimicrob Agents Chemother 1991; 35:983-5.
36. Marchou B, Michea-Hamzehpour M, Lucain C, Pechere JC. Development of beta-lactam-resistant Enterobacter cloacae in mice. J Infect Dis 1987; 156:369-73.
37. Sanders WE Jr., Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23:454-61.
38. Choi SH, Lee JE, Park SJ, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008; 52:995-1000.
39. Hilty M, Sendi P, Seiffert SN, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents 2013; 41:236-49.
40. Schmidtke AJ, Hanson ND. Model system to evaluate the effect of AmpD mutations on AmpC-mediated beta-lactam resistance. Antimicrob Agents Chemother 2006; 50:2030-7.
41. Tamma PD, Wu H, Gerber JS, et al. Outcomes of children with Enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes? [ePub ahead of print] Pediatr Infect Dis J 2013.
42. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Bottger EC, Hombach M. Practical approach for reliable detection of AmpC beta-lactamaseproducing Enterobacteriaceae. J Clin Microbiol 2011; 49:2798-803.
43. Choi SH, Kim YS, Chung JW, et al. Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect Control Hosp Epidemiol 2002; 23:740-7.
44. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. Document M100-S22.Wayne, PA: CLSI, 2012.
45. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002; 137:693-5.